Latest News and Press Releases
Want to stay updated on the latest news?
-
Dublin, April 14, 2026 (GLOBE NEWSWIRE) -- The "Preparing for GCP Inspections: Key Expectations under ICH GCP E6(R3), EU CTR and Current Regulatory Thinking (July 13, 2026)" training has been added...
-
Dublin, April 14, 2026 (GLOBE NEWSWIRE) -- The "Clinical Research Project Management (April 29, 2026 and May 1, 2026)" training has been added to ResearchAndMarkets.com's offering.This interactive...
-
Dublin, April 14, 2026 (GLOBE NEWSWIRE) -- The "Pharmacovigilance: An Overview of Drug Safety from Safety Collection to Regulatory Inspection (Apr 30, 2026)" training has been added to ...
-
Dublin, April 09, 2026 (GLOBE NEWSWIRE) -- The "Biopharmaceutical CMO & CRO Market - Global Forecast 2026-2032" report has been added to ResearchAndMarkets.com's offering. The...
-
NEW YORK, USA, April 08, 2026 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled “Functional Service Providers Market By Type (Clinical Monitoring, Medical Writing,...
-
Marvel announces financial and strategic backing from 5 Horizons Ventures to support its upcoming Phase 1 clinical trial of patented lead asset MB-204
-
Marvel Biosciences secures $600,000 in non-dilutive funding from Alberta Innovates to support Phase I clinical trials of its autism-focused patented MB-204
-
PALO ALTO, Calif. and TEL AVIV, March 26, 2026 (GLOBE NEWSWIRE) -- Exodigo, the artificial intelligence (AI) and multi-sensing innovator transforming underground data intelligence, today announced...
-
Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204, lead asset discovery, a patented neuroactive adenosine A2A antagonist
-
Dublin, March 20, 2026 (GLOBE NEWSWIRE) -- The "Decentralized Clinical Trials: Global Markets" has been added to ResearchAndMarkets.com's offering. The Decentralized Clinical Trials Market is...